Biotech Layoffs Surge: Theravance Halves Staff, BioAtla Cuts 70%

The biotech industry is facing another brutal stretch of layoffs in early 2026. Theravance Biopharma is cutting roughly half its workforce after a pivotal phase 3 trial failure. BioAtla is slashing approximately 70% of its staff as it explores strategic alternatives. And EveryOne Medicines shut down entirely on March 3. These are not isolated events. They are part of an accelerating pattern in which clinical trial failures, FDA rejections, and dwindling cash runways are forcing biotech companies to make devastating workforce decisions. For the thousands of specialized scientists, researchers, and support staff caught in these cuts, the path forward requires a clear-eyed look at where the industry stands and what opportunities remain.

What Happened at Theravance Biopharma?

Theravance Biopharma announced in early March 2026 that it would cut approximately 50% of its workforce and end all research and development activity. The Dublin- and San Francisco-based company had been developing ampreloxetine, a selective norepinephrine reuptake inhibitor, as a treatment for symptomatic neurogenic orthostatic hypotension, a rare condition that causes dangerous drops in blood pressure upon standing. The drug was tested in a phase 3 study called CYPRESS involving 102 patients, but it missed its primary endpoint, which measured changes in dizziness, lightheadedness, blurred vision, weakness, and fainting symptoms at Week 8.

This was not the first setback for ampreloxetine. The drug had previously failed another pivotal study, making the CYPRESS failure a decisive blow to the company's entire R&D pipeline. According to Fierce Biotech, the restructuring is expected to reduce Theravance's cash burn by 60%, saving approximately $70 million through the third quarter of 2026.

Going forward, Theravance will focus exclusively on Yupelri, its approved nebulized bronchodilator for chronic obstructive pulmonary disease, from which it expects to generate $60 to $70 million in annualized cash flow through a partnership with Viatris. The company's board has also begun reviewing strategic alternatives, which could include a sale. The layoffs will be implemented over the next two quarters, meaning affected employees face an extended period of uncertainty before final separations take effect.

Why Is BioAtla Cutting 70% of Its Workforce?

San Diego-based BioAtla disclosed on March 2, 2026, that it had committed to a restructuring plan that will eliminate approximately 70% of its workforce. The company is retaining only those employees deemed essential to a formal review of strategic options, which could include asset sales, licensing deals, partnerships, or other transactions.

This is the second major round of cuts at BioAtla in less than a year. The company previously slashed 30% of its staff in a move intended to extend its cash runway into the first half of 2026. That lifeline has now run its course. According to an SEC filing reported by BioSpace, the total cash cost of the 70% reduction is estimated at $500,000 to $600,000 in severance and benefits, with most payments expected in the first quarter of 2026.

As part of the restructuring, Chief Financial Officer Richard Waldron's employment was terminated effective March 2, with Chris Vasquez promoted to the role. When a company changes its CFO during a restructuring while simultaneously exploring strategic alternatives, it typically signals that leadership is preparing the business for a transaction rather than a turnaround. For BioAtla employees, the practical reality is that most remaining positions are likely temporary, tied to the timeline of whatever deal the board ultimately pursues.

What Happened to EveryOne Medicines?

EveryOne Medicines closed its doors on March 3, 2026, becoming one of the most notable biotech shutdowns of the year. The company was pioneering individualized therapies for patients with genetically unique diseases, essentially developing custom treatments for extremely small patient populations.

The closure was driven by the practical challenges of working within the FDA's bespoke regulatory framework for personalized medicines. Under this framework, each individualized treatment is treated as a separate application, requiring a full submission package built from scratch every time. For a small biotech without the resources of a major pharmaceutical company, that regulatory burden proved unsustainable. According to Endpoints News, the company had banked its future on a new FDA pathway that ultimately did not provide the streamlined process it needed to survive.

The EveryOne Medicines closure highlights a broader tension in the biotech industry. Precision medicine and individualized therapies represent the scientific frontier, but the regulatory and commercial infrastructure has not kept pace with the science. Companies working on treatments for ultra-rare conditions face a fundamental mismatch between the cost of development and the size of the market they can serve.

How Bad Are Biotech Layoffs in 2026?

The early months of 2026 have delivered a steady drumbeat of biotech workforce reductions. Beyond Theravance, BioAtla, and EveryOne Medicines, several other companies have announced significant cuts. Disc Medicine is laying off approximately 20% of its workforce, or about 30 people, primarily in commercial roles, after the FDA rejected its rare blood disease drug bitopertin over concerns about using a surrogate endpoint instead of clinical outcomes. GSK announced that up to 350 positions could be eliminated across its U.S. and U.K. operations. Merck revealed layoffs of 147 staffers at its vaccine manufacturing plant in Durham, North Carolina.

According to BioSpace's layoff tracker, biopharma companies let go of fewer than 500 people in the first month of 2026, down nearly 1,000 from January 2025. That comparison offers some hope that the pace of cuts may be stabilizing. However, the nature of the layoffs is shifting. In 2025, biopharma layoffs rose 16% year over year according to Fierce Biotech's annual tracker. Many of those cuts were driven by post-COVID cash corrections as companies that raised capital during the pandemic funding boom ran through their reserves.

In 2026, the primary driver has shifted to clinical trial failures and FDA regulatory setbacks. A plethora of drug programs funded during the pandemic are now reaching late-stage readouts, and more readouts mathematically means more failures. EY analysts project that the total percentage of biopharma workforce layoffs in 2026 will likely stay below 5%, according to PharmaVoice. But for workers at companies like Theravance and BioAtla, industry-wide averages are cold comfort when your entire team is being dissolved.

What Should Biotech Workers Do After a Layoff?

If you work in biotech and have been laid off or suspect cuts are coming, there are concrete steps you can take to position yourself for what comes next.

Identify Your Transferable Skills

Biotech professionals often underestimate how broadly their skills apply. Clinical research associates, regulatory affairs specialists, data scientists, quality assurance managers, and lab technicians all possess expertise that transfers directly to adjacent industries. Medical device companies, contract research organizations, healthcare technology firms, and even government agencies like the FDA and NIH regularly hire people with biotech backgrounds. The key is to reframe your experience in terms of the outcomes you delivered rather than the specific drug or therapy you worked on.

Consider the Pharma Pivot

Large pharmaceutical companies like Pfizer, Johnson & Johnson, Roche, and AbbVie continue to invest heavily in R&D and often absorb talent from smaller biotechs that have downsized. While big pharma roles may feel less entrepreneurial, they offer stability, deeper pipelines, and more diversified risk. Many pharma companies are also expanding their cell therapy, gene therapy, and AI-driven drug discovery divisions, creating new roles that did not exist even two years ago.

Explore Contract and Consulting Roles

The biotech industry has increasingly shifted toward a contract workforce model, especially for clinical trial operations, regulatory submissions, and specialized laboratory work. Contract research organizations like IQVIA, Labcorp Drug Development, and Syneos Health regularly hire experienced biotech professionals on project-based terms. These roles can serve as a bridge between positions, keep your skills current, and often lead to permanent placements.

Upskill in High-Demand Areas

The biotech jobs market increasingly rewards professionals who combine traditional scientific expertise with technology skills. AI-driven drug discovery, bioinformatics, real-world evidence analysis, and digital health are all areas experiencing talent shortages. Online certifications in data science, machine learning for life sciences, or regulatory technology can differentiate your resume in a crowded job market.

Network Aggressively

Biotech is a relationship-driven industry. Former colleagues who landed at other companies, vendors you worked with, and contacts from industry conferences are all potential pathways to your next role. Many biotech positions are filled through referrals before they are ever posted publicly. Update your professional profiles, reach out to your network, and attend industry events like the BIO International Convention and JP Morgan Healthcare Conference networking sessions.

What Does This Mean for the Broader Job Market?

Biotech layoffs matter beyond the industry itself. The life sciences sector is a significant employer in research hubs like Boston, San Francisco, San Diego, and the Research Triangle in North Carolina. When companies like Theravance and BioAtla cut staff, the effects ripple through local economies, from the landlords who lease lab space to the restaurants and services that depend on biotech workers' spending.

On a national level, biotech job losses also reflect broader challenges in the innovation economy. Drug development is inherently risky, with only about 10% of drugs that enter clinical trials ultimately receiving FDA approval. The current wave of layoffs is partly a correction from the over-investment of the pandemic era, when low interest rates and urgent demand for mRNA technology attracted record capital into biotech. As that capital has been spent and interest rates remain elevated, companies without approved products or near-term revenue are running out of options.

For job seekers outside of biotech, the lesson is instructive. Industries built on long development timelines and binary regulatory outcomes carry concentrated employment risk. Diversifying your skills across adjacent fields, maintaining a financial cushion, and building a professional network are not just career advice. They are essential risk management in any industry where a single clinical trial result or regulatory decision can eliminate your entire team overnight.

People Also Asked

Q: Why are so many biotech companies laying off workers in 2026?

A: The primary drivers are clinical trial failures and FDA regulatory setbacks. Many biotech companies raised significant capital during the pandemic era and are now reaching late-stage drug readouts. When those trials fail, companies that lack diversified pipelines or approved products are forced to restructure or shut down entirely. Elevated interest rates have also made it harder for pre-revenue biotechs to raise new funding, accelerating the timeline from trial failure to workforce reduction.

Q: What types of biotech jobs are most at risk during layoffs?

A: When a biotech company's lead drug candidate fails, R&D roles directly tied to that program are typically cut first, including clinical research staff, laboratory scientists, and regulatory affairs specialists focused on the failed submission. Commercial teams are also vulnerable, as seen with Disc Medicine's cuts, because there is no longer a product to bring to market. Support functions like HR, finance, and operations are often reduced proportionally. Companies exploring strategic alternatives, like BioAtla, tend to retain only the minimum staff needed to manage a potential sale or licensing deal.

Q: Where are biotech workers finding new jobs after layoffs?

A: Many laid-off biotech professionals are moving into large pharmaceutical companies that continue to invest in R&D, particularly in cell therapy, gene therapy, and AI-driven drug discovery. Contract research organizations like IQVIA and Labcorp Drug Development are actively hiring experienced biotech talent for project-based roles. Medical device companies, healthcare technology firms, and government agencies including the FDA and NIH also regularly recruit from the biotech talent pool. Professionals who upskill in bioinformatics, data science, or digital health are finding the strongest demand for their expertise.

Looking for your next opportunity? Whether you're navigating a biotech layoff or exploring a career pivot into pharma, healthcare tech, or contract research, Metaintro delivers curated job market insights and opportunities directly to your inbox. Sign up for free and take the next step in your career today.